{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:12:54Z","timestamp":1791432774012,"version":"4.3.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2K24DK085446"],"award-info":[{"award-number":["2K24DK085446"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32DK007357"],"award-info":[{"award-number":["5T32DK007357"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.mayocp.2020.12.038","type":"journal-article","created":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T20:12:52Z","timestamp":1619986372000},"page":"2114-2122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Barriers to ACEI\/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6470-6959","authenticated-orcid":false,"given":"Ian E.","family":"McCoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Montez-Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mayocp.2020.12.038_bib1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2020.12.038_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2020.12.038_bib3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.mayocp.2020.12.038_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2020.12.038_bib5","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1016\/j.mayocp.2020.12.038_bib8","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1681\/ASN.2019090869","article-title":"Measuring quality in kidney care: an evaluation of existing quality metrics and approach to facilitating improvements in care delivery","volume":"31","author":"Mendu","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.mayocp.2020.12.038_bib10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2215\/CJN.00060119","article-title":"Trends in quality of care for patients with CKD in the United States","volume":"14","author":"Tummalapalli","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.mayocp.2020.12.038_bib11","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocp.2020.12.038_bib12","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"9","key":"10.1016\/j.mayocp.2020.12.038_bib13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mayocp.2020.12.038_bib14","unstructured":"National Collaborating Centre for Chronic Conditions (UK). Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London: Royal College of Physicians (UK). 2018."},{"issue":"11","key":"10.1016\/j.mayocp.2020.12.038_bib15","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.mayocp.2019.05.031","article-title":"Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease","volume":"94","author":"Qiao","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2020.12.038_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/HYPERTENSIONAHA.118.12060","article-title":"Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus","volume":"73","author":"Ohkuma","year":"2019","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.mayocp.2020.12.038_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor\u2013associated elevations in serum creatinine; is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mayocp.2020.12.038_bib18","unstructured":"National Institute for Health and Care Excellence Chronic kidney disease in adults: assessment and management: Clinical guideline [CG182]. NICE, 2014. https:\/\/www.nice.org.uk\/guidance\/cg182. Accessed April 1, 2020."},{"issue":"6","key":"10.1016\/j.mayocp.2020.12.038_bib19","first-page":"E13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.mayocp.2020.12.038_bib20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2018-314158","article-title":"Change in renal function associated with drug treatment in heart failure: national guidance","volume":"105","author":"Clark","year":"2019","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.mayocp.2020.12.038_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2215\/CJN.14021118","article-title":"Stopping RAS inhibitors to minimize AKI more harm than good?","volume":"14","author":"Tomson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.mayocp.2020.12.038_bib22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256","article-title":"Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction","volume":"4","author":"Testani","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.mayocp.2020.12.038_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/2054358118804838","article-title":"Kidney function, ACE-inhibitor\/angiotensin receptor blocker use, and survival following hospitalization for heart failure: a cohort study","volume":"5","author":"Chiu","year":"2018","journal-title":"Can J Kidney Health Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2020.12.038_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.mayocp.2020.12.038_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.ajkd.2019.11.010","article-title":"AKI\u2014a relevant safety end point?","volume":"75","author":"McCoy","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.mayocp.2020.12.038_bib26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin angiotensin aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail"},{"issue":"3","key":"10.1016\/j.mayocp.2020.12.038_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1755-5922.2010.00258.x","article-title":"Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"30","author":"Raebel","year":"2012","journal-title":"Cardiovasc Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2020.12.038_bib28","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney Int"},{"issue":"10208","key":"10.1016\/j.mayocp.2020.12.038_bib29","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2020.12.038_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1468-5914.1986.tb00074.x","article-title":"Tradeoffs among reasons for action","volume":"16","author":"Baron","year":"1986","journal-title":"J\u00a0Theory Soc Behav"},{"issue":"1","key":"10.1016\/j.mayocp.2020.12.038_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/scientificamerican0182-160","article-title":"The psychology of preferences","volume":"246","author":"Kahneman","year":"1982","journal-title":"Sci Am"},{"issue":"11 suppl","key":"10.1016\/j.mayocp.2020.12.038_bib32","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Murray","year":"2015","journal-title":"Am J Manag Care"},{"issue":"22","key":"10.1016\/j.mayocp.2020.12.038_bib33","doi-asserted-by":"crossref","first-page":"e012655","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin\u2013angiotensin\u2013aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.mayocp.2020.12.038_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1370\/afm.1302","article-title":"Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States","volume":"9","author":"Plantinga","year":"2011","journal-title":"Ann Fam Med"},{"issue":"24","key":"10.1016\/j.mayocp.2020.12.038_bib35","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.mayocp.2020.12.038_bib36","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621000690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621000690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T04:52:56Z","timestamp":1698987176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619621000690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0025619621000690"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.12.038","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers to ACEI\/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}